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 CURRENTOPINION The role of regulatory B cells in
allergen immunotherapy
Willem van de Veena,b
Purpose of review
Allergen immunotherapy (AIT) is currently the only curative treatment available for allergic diseases, and
has been used in clinical practice for over a century. Induction and maintenance of immune tolerance to
nonhazardous environmental and self-antigens is essential to maintain homeostasis and prevent chronic
inflammation. Regulatory B (BREG) cells are immunoregulatory cells that protect against chronic
inflammatory responses primarily through production of anti-inflammatory cytokines such as IL-10,
transforming growth factor-b, and IL-35. The importance of BREG cells has been extensively demonstrated in
the context of autoimmune diseases. Data showing their role in the regulation of allergic responses are
slowly accumulating. This review summarizes recent findings relevant to the topic of BREG cells and their
potential role in AIT.
Recent findings
BREG cells support AIT in models of allergic airway inflammation and intestinal inflammation through
induction of regulatory T (TREG) cells. In humans BREG frequency increases during venom immunotherapy
while the phenotype of allergen-specific B cells changes. Mechanisms of BREG-mediated tolerance to
allergens include IL-10-mediated suppression of effector T cell, including TH2 responses, induction of TREG
cells, IL-10-mediated inhibition of Dendritic cell maturation, modulation of T follicular helper responses, and
production of anti-inflammatory IgG4 antibodies.
Summary
Current evidence supports a potential role for BREG cells in induction and maintenance of allergen tolerance
during AIT. A better understanding of the role of B cells and BREG cells in AIT could open potential new
windows for developing targeted therapies specifically focused on promoting BREG responses during AIT.
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INTRODUCTION
Allergen immunotherapy (AIT) has been used as a
curative treatment for allergies for more than a
century and many of its underlying mechanisms
have been elucidated. These include early desensiti-
zation of mast cells and basophils, induction of
Regulatory T (TREG) cells, production of allergen-
specific IgG (particularly IgG4) antibodies, suppres-
sion of eosinophil activation and migration [1,2]. In
addition, several recent studies suggest a potential
role for regulatory B (BREG) cells in AIT [3].
PHENOTYPE AND FUNCTION OF
REGULATORY B CELLS
BREG cells exhibit anti-inflammatory functions, and
their immunosuppressive role has been demon-
strated to varying degrees in autoimmune disease,
cancer, transplantation, infection, and allergic
inflammation [3,4].
SUPPRESSIVE MECHANISMS OF
REGULATORY B CELLS
BREG cells act primarily through secretion of the
immune-modulatory cytokines [3]. Most studies
have focused on the role of IL-10 as the key factor
through which BREG cells modulate immune
responses and protect against excessive inflamma-
tion [5–10]. IL-10 has a wide range of suppressive
effects on different cells types and has been widely
recognized as an immune tolerance-inducing factor
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in patients with different chronic inflammatory
diseases [11]. Transforming growth factor-b
(TGF-b) has also been identified as BREG-associated
suppressor molecule. TGF-b is involved in many
processes including tissue remodelling and immune
regulation. An important role for TGF-b in the con-
text of immune tolerance is its capacity to support
conversion of naive CD4þ T cells to TREG cells [11].
Finally, IL-35 has also been linked to BREG-mediated
immune suppression [12]. IL-35 can promote
immune tolerance through induction of TREG pro-
liferation and suppression of TH17 responses [11].
Apart from secreted cytokines, other molecules
have been associated with BREG-mediated suppres-
sive effects. These include the membrane-associated
molecules such as CD19 [13], CD62L and MHC-II
[14], fas ligand [15], T-cell immunoglobulin and
mucin domain [16], and programmed death ligand
1 [8,17–20], as well as the intracellular signalling
molecules signal transducer and activator of tran-
scription 3 and myeloid differentiation response
gene 88 [21].
In the context of human allergen tolerance
induction, the production of IgG4 antibodies
deserves some attention. IgG4 is considered to com-
pete with IgE for allergen binding and thereforemay
function as a blocking antibody. Some unique fea-
tures of IgG4 such as antigen-binding fragment-arm
exchange, its low affinity for activating fragment
crystallizable receptors, and its inability to fix com-
plement render IgG4 an anti-inflammatory immu-
noglobulin isotype [22,23].
One of the mechanisms through which BREG
cells could play a role in AIT, is through the modu-
lation of T-cell responses. BREG cells have been
shown to induce TREG cells in several different mod-
els [3,24,25]. Apart from induction of TREG cells,
BREG cells could support AIT through suppression
of effect T-cell proliferation and cytokine produc-
tion [8,26]. A recent study provided compelling data
demonstrating that BREG cells could modulate T
follicular helper (TFH) cell responses. Cocultures of
in-vitro generated human TFH cells with B cells
resulted (as expected) in plasma cell and memory
cell differentiation. Upon addition of B cells that
were stimulated for 3 days with CD40L and TLR9-
ligand CpG2006 (these cells were considered BREG in
this study), the B-cell differentiation was inhibited,
and forkhead box (FoxP)3þC-X-C chemokine recep-
tor (CXCR)5þ programmed death ligand-1þ regula-
tory TFH were expanded. CD40, CD80, CD86, as well
as IL-10 and TGF-b played a role in this process.
These findings suggest that BREG cells can interfere
with germinal centre reactions through modulation
of TFH cells [27
&
]. A weakness in this study is the fact
that stimulated total B cells were used as BREG,
whereas only a fraction of these cells can be consid-
ered BREG cells. Some of these findings were corrob-
orated in amurine cardiac transplantationmodel, in
which marginal zone B-cell-derived IL-10 proved
essential for induction of regulatory TFH cells and
tolerance toward the allograft [28].
DIFFERENT SUBSETS OF REGULATORY B
CELLS
A number of different human and murine BREG cells
have been identified based on phenotypic and func-
tional characteristics. It goes beyond the scope of
this review to describe all BREG subsets in detail and
comprehensive reviews on this topic have been
published elsewhere [3,4]. In the mouse system,
BREG cells are found among cells with a B1a-like cells
(i.e. CD5þ B cells) [29], among B cells with an
immature/transitional phenotype [30,31], and
among cells with a plasma cell phenotype [32]. In
the human system, the major phenotypes of BREG
cells are CD27þCD24hiCD148hiCD48hi B10/pro-B10
cells [18], CD24hiCD38hi immature B cells [20],
CD73CD25þCD71þ type 1 regulatory B (BR1) cells,
and CD27intCD38þ/hi plasmablasts [3,17,32].
REGULATORY B CELLS AND THEIR ROLE
IN TOLERANCE INDUCTION TO
ALLERGENS
The majority of studies on BREG cells have focused
on their role in autoimmune diseases. However, an
increasing body of evidence supports a potential
role for BREG cells in maintaining and restoring
tolerance to allergens. Several recent studies provide
support for a role for BREGs in AIT. Mechanisms
through which BREGs could support AIT include
induction of TREG cells, direct suppression of
effector T cells, indirect suppression of effector T
cells through inhibition of Dendritic cell (DC)
KEY POINTS
 Current evidence supports a potential role for BREG cells
in induction and maintenance of allergen tolerance.
 IL-10-producing BREG cells expand during AIT in murine
models of allergic airway and intestinal inflammation,
as well as in human VIT.
 BREG cells may contribute to tolerance induction during
AIT include IL-10-mediated suppression of effector T
cell, including TH2 responses, induction of TREG cells,
IL-10-mediated inhibition of DC maturation, modulation
of TFH responses, and production of anti-inflammatory
IgG4 antibodies.
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maturation, and production of IgG4 antibodies.
Studies focusing on mouse models of allergic dis-
ease, primarily demonstrated a role for BREG cells
with a B1a-like phenotype [10,26,33], whereas
human studies focused on allergic disease primarily
reported on BR1 cells [8,34
&
,35].
REGULATORY B CELLS IN INDUCTION
AND MAINTENANCE OF TOLERANCE TO
ALLERGENS IN HUMANS
The aim of AIT is typically to restore clinical and
immunological tolerance to allergens [36]. This
requires the alteration of a TH2 and IgE-dominated
allergic response toward a healthy immune
response. Healthy immune responses to allergens
have been studied primarily in cat owners and bee-
keepers. Hallmarks of a healthy response to allergens
are induction of IL-10-producing inducible type 1
regulatory T (TR1) cells and blocking IgG(4) anti-
bodies [37].
A human BREG subset that has been studied in
the context of tolerance to allergens are
CD73CD24þCD71þ BR1 cells [8]. These cells could
efficiently suppress antigen-specific CD4þ T-cells
proliferation. Data supporting a role for human BREG
cells in developing tolerance to allergens comes
primarily from studies on bee venom allergic indi-
viduals and healthy beekeepers. B cells specific for
the major bee venom allergen phospholipase A2
(PLA) were identified using fluorescently labelled
PLA. The frequency of IL-10-producing B cells
among these allergen-specific B cells showed a
two to five-fold increase in bee venom allergic
patients at 3–4 months after the start of venom
immunotherapy (VIT). After this increase the fre-
quency of PLA-specific IL-10-producing B cells was
at a comparable level as in healthy beekeepers dur-
ing the season [8]. It remains to be elucidated
whether allergen-specific B cells upregulate IL-10
production during VIT, or preexisting IL-10-produc-
ing allergen-specific B cells proliferate during VIT.
Apart from IL-10, allergen-specific B cells also upre-
gulated C-C chemokine receptor (CCR)5, a receptor
for Macrophage Inflammatory Protein 1a and b as
well as regulated on activation, normal T cell
expressed and secreted, during VIT [34
&
]. Although
CCR5 expressed on TREG cells has been found to
mediate their migration to inflammatory sites [38],
its function on allergen-specific BREG cells remains
to be determined.
The frequency of circulating allergen-specific B
cells has been shown to increase during peanut
immunotherapy and VIT [34
&
,39,40
&&
]. A fraction
of these cells may be IL-10þ allergen-specific B cells
[8]. In accordance with increases in serum levels of
allergen specific IgG4 of that are frequently observed
during AIT [36], it was primarily expansion of aller-
gen-specific IgG4-switched B cells that drove this
increase of allergen-specific B cells during VIT [34
&
].
Increases in specific IgG4 during AIT correlate with
clinical outcome in some, but not all studies [36].
One intriguing possibility is that not just an increase
of specific IgG4 is sufficient for clinical improve-
ment but rather the generation of high-affinity-spe-
cific IgG4 antibodies. This concept is technically
challenging to prove, but recent work indicates that
IgG4 (but not IgE)-switched peanut allergen-specific
B cells accumulate an increasing proportion of more
highly mutated sequences over time during the
course of peanut oral immunotherapy [40
&&
]. As
increased levels of somatic mutations are indicative
of affinity maturation [41], these data suggest that
IgG4 antibodies increase their affinity during AIT.
Very interesting in the context of a potential
role for BREG cells during AIT is the link between
IL-10-producing BR1 cells and IgG4 production.
Purified IL-10-producing B cells produced signifi-
cantly increased levels of IgG4 antibodies compared
to IL-10 B cells, whereas other immunoglobulin
isotypes were produced in comparable amounts by
IL-10þ and IL-10 cells [8]. Thus, BR1 may promote
allergen tolerence during AIT through IL-10-
mediated suppressive effects and through directing
the humoral response toward IgG4.
REGULATORY B CELLS IN MOUSE
MODELS OF TOLERANCE INDUCTION IN
ALLERGIC AIRWAY INFLAMMATION
B cells can induce allergen tolerance through pro-
duction of TGF-b as was demonstrated in an oval-
bumin (OVA)-induced airway inflammation and
tolerance model. Mice that were administered a
short-term (7 day) daily intranasal OVA exposure
developed sensitization, whereas chronically
exposed mice (42-day exposure) developed toler-
ance. Adoptively transferred B cells isolated from
hilar lymph nodes of chronically exposed mice sup-
pressed allergic airway inflammation in sensitized
recipient mice. This suppressive effect was indepen-
dent of IL-10, as B cells isolated from tolerant IL-10/
 mice exerted similar suppressive capacity [42].
Later it was found that CD5þCD1dhi B cells were
expanded in hilar lymph nodes of tolerant mice.
These cells produced TGF-b and induced FoxP3
expression in CD4þ T cells in vitro and suppressed
development of allergic airway inflammation in vivo
via enhanced accumulation of Foxp3þ T cells in the
lung [24].
A recent study with a different approach dem-
onstrated that development of OVA-induced airway
Bregs in allergen immunotherapy van de Veen
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inflammation and tolerance induction were devel-
oped similarly in wild-type (WT) and B cell-deficient
(mMT) mice, indicating that B cells are not required
for establishing OVA-induced airway inflammation.
Tolerance could be induced by pretreatment with a
high dose of intranasally administered OVA both in
WT and mMT mice, suggesting that B cells were
dispensable for tolerance induction in this model.
IL-10 production by purified splenic B cells in
response to lipopolysaccharide stimulation from
OVA-sensitized and tolerized showed a similar and
modest increase compared with control mice [25].
The effect of TGF-b production was not assessed
in this study. It is interesting to note here that
OVA-induced airway inflammation was accompa-
nied by elevated germinal centre B cells numbers
and elevated specific immunoglobulin production,
whereas these B cell alterations were attenuated
upon tolerance induction. Moreover, marginal zone
precursor B cells from tolerant mice could induce
TREG cells in vitro [25].
Methodological differences (e.g. application
routes, dosing schemes, B cell-deficient mice vs.
adoptive transfer experiments) may partially
explain the seemingly different conclusions of these
studies. However, taken together these datapoint
out that in high-dose OVA tolerance induction
models for allergic airway inflammation, BREG cells
can be induced or expanded. These BREG cells have
the capacity to induce TREG cells and, upon adoptive
transfer, confer allergen tolerance in sensitized
recipient mice in an IL-10-independent manner.
TGF-b could be the driving factor in this process.
These BREG cells may therefore contribute to aller-
gen-tolerance induction in such an AIT model but
the fact that B cell-deficient mice still develop toler-
ance indicates that there is redundancy with other
suppressor cells.
FIGURE 1. Mechanisms of BREG-mediated immunoregulatioin during AIT. IL-10 and TGF-b can be produced by BREG cells.
IL-10 can suppress effector T-cell responses directly but also indirectly through suppression of DC maturation. IL-10 produced
by BREG cells may promote IgG4 production in an autocrine, as well as a paracrine manner. Both BREG cells can induce TREG
cells through IL-10 and TGF-b. AIT, allergen immunotherapy; BREG, regulatory B; TGF, transforming growth factor.
Immunotherapy and new treatments
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REGULATORY B CELLS IN MOUSE
MODELS OF TOLERANCE INDUCTION IN
ALLERGIC INTESTINAL INFLAMMATION
Similar to what was found in models of allergic
airway inflammation, B-cell-derived TGF-b may
play a key role in tolerance induction to food aller-
gens. A fraction of CD5þCX3CR1þ B cells present in
the intestine of naive Bagg albino mice produced
TGF-b in response to stimulation with avb6 and a
B cell receptor (BCR) crosslinking antibody. Intesti-
nal epithelial cells may recruit CD5þCX3CR1þ B
cells, through production of fractalkine, which is
a ligand for CXCR3. Food antigen-specific
CD5þCX3CR1þ B cells could form a local source
of TGF-b upon encounter of their cognate antigen
and epithelial cell-derived avb6. Adoptive transfer
of CD5þCX3CR1þ B cells could ameliorate TH2-
mediated intestinal inflammation [26]. A factor that
may promote TGF-b production by B cells is throm-
bospondin 1, which enhances generation of active
TGF-b. Whenmice sensitized with OVA and cholera
toxin (to induce intestinal inflammation) received
an AIT regimen in the form of increasing doses of
gavage-fedOVA, CD35þ B cells in the lamina propria
increased in frequency and produced thrombospon-
din 1 [43].
CONCLUSION
AIT has been used with considerable success for over
a century. Increasingly detailed knowledge has been
accumulated on the immunological mechanisms
that drive successful clinical outcome of this ther-
apy. BREG cells have only recently been identified as
potentially relevant cells in the induction andmain-
tenance of allergen tolerance. Currently available
data suggest potential roles for BREG cells in AIT
treatment of allergic airway inflammation, food
allergies, and venom allergies. Mechanisms through
which BREG cells may contribute to tolerance induc-
tion during AIT are summarized in Fig. 1 and include
IL-10-mediated suppression of effector T cell,
including TH2 responses [8,26], induction of TREG
cells [24,25], IL-10-mediated inhibition of DC mat-
uration [44], modulation of TFH responses [27
&
,28],
and production of anti-inflammatory IgG4 antibod-
ies [8,34
&
]. A better understanding of the role of B
cells and BREG cells in AIT could open up potential
windows for developing targeted therapies specifi-
cally focused on promoting BREG responses during
AIT.
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